Goals:

• Primary:

  • Gain unique insights into therapeutic outcomes of men with prostate cancer treated with PARP inhibitors that will inform optimal patient selection, management, and novel scientific directions.

• Secondary:

  • Develop proposals for optimal clinical and genomic data collection to inform future PARPi candidacy and clinical practice.

  • Analyze responses to PARP inhibitors among prostate cancer patients with DNA repair mutations.

  • Develop and validate prognostic models of genomic markers on PARPi clinical outcomes

  • Identify genomic modifiers of PARPi response and duration of response.